Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
72.5(c) 73.59(c) 72.78(c) 76.31(c) 75.62 Last
8 486 148 5 638 379 5 198 576 7 455 148 5 455 160 Volume
-3.05% +1.50% -1.10% +4.85% -0.90% Change
More quotes
Financials (USD)
Sales 2018 21 414 M
EBIT 2018 11 251 M
Net income 2018 6 653 M
Debt 2018 9 803 M
Yield 2018 2,98%
Sales 2019 21 522 M
EBIT 2019 11 294 M
Net income 2019 7 160 M
Debt 2019 8 768 M
Yield 2019 3,22%
P/E ratio 2018 15,15
P/E ratio 2019 13,93
EV / Sales2018 4,91x
EV / Sales2019 4,84x
Capitalization 95 398 M
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey,... 
Sector
Biotechnology & Medical Research
Calendar
10/25 | 10:01pmEarnings Release
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
10/11GILEAD SCIENCES : to Release Third Quarter 2018 Financial Results on Thursday, O..
BU
10/11GILEAD SCIENCES : to Present Wide-Ranging New Data on Treatment and Diagnosis of..
BU
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/10GILEAD SCIENCES : Polaris, Arch co-lead series A for MIT spinout Glympse
AQ
10/09GILEAD SCIENCES : NHS England reaches deal with Gilead on CAR-T therapy Yescarta
AQ
10/09GILEAD SCIENCES : strikes deal with NHS England on Yescarta access
AQ
10/08GILEAD SCIENCES : NHS, Gilead reach agreement for Yescarta
AQ
10/06GILEAD SCIENCES : NHS England appoves Gilead`s CAR T therapy Yescarta
AQ
10/05GILEAD SCIENCES : Hong Kong Department of Health Approves Biktarvy
AQ
10/05GILEAD SCIENCES : Announces 96-Week Results from Phase 3 Study of Biktarvy for t..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
More sector news : Bio Therapeutic Drugs
MarketScreener Strategies on GILEAD SCIENCES 
GILEAD SCIENCES - 2014
A valuable trading opportunity
BUY
GILEAD SCIENCES - 2014
Continuation of the bullish trend
BUY
More Strategies
Latest Tweets
10/17Gilead's HIV prevention pill can greatly reduce new infections in targeted ro.. 
10/17Leerink Swann Raises Gilead Sciences Q3 2018 Earnings Estimates to $1.60 EPS .. 
10/17Head to Head Analysis: Gilead Sciences $GILD and NOVOZYMES A/S/S $NVZMY  
10/16RECAP 10/16 Unusual Calls: $QCOM $IRWD $IGT $TSLA $SSNC $SLV $ABX $GRPN $LAD ..
3
10/16$AAPL $AMGN $AMZN $BIIB $BRK.B $CELG $GE $GILD $GOOGL $GS $INTC $JPM $M $MS $.. 
More tweets
Qtime:430
News from SeekingAlpha
10/1610 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targe.. 
10/15FDA issues new guidance aimed at more efficient drug development 
10/15GILEAD IN PBC : The Clinical Pursuit For Dominance 
10/15Healthcare 16-24% Target Net Gains Pace WallStars For October 
10/15Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends 
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 87,9 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671
GENMAB-11.78%8 632